| Drug / Therapy | Varegacestat |
| Indication | IMNM PDUFA |
| Decision Type | PDUFA |
| Conditions | IMNM PDUFA |
| Interventions | Varegacestat |
Immunome, Inc. (IMNM) operates in the Immunology sector. The current BiotechSign Score is 25 (Grade: F).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The PDUFA date for Varegacestat by Immunome, Inc. (IMNM) is scheduled for April 28, 2027. This is the target date for the FDA to make a decision on this application.
Varegacestat is being developed by Immunome, Inc. for the treatment of IMNM PDUFA. It is under FDA review.
If Varegacestat receives FDA approval, Immunome, Inc. (IMNM) would be able to market the drug in the United States for IMNM PDUFA. This typically leads to significant stock price movement for biotech companies. Investors should monitor the PDUFA date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for IMNM on DilutionWatch at dilutionwatch.com/stock/IMNM.html.
You can view the full BiotechSign company profile for Immunome, Inc. (IMNM) at biotechsign.com/app/company/IMNM, which includes the BiotechSign Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSign is not a registered investment advisor.